Search Results 741-750 of 1997 for 搜索引擎平台开发咨询邮箱：lgooxc@hotmail.com
In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease progression. If a complete response is observed, ...
A multidisciplinary faculty guides research in the Mayo Clinic Alzheimer's Disease Research Center.
About this study. This phase II trial studies how well sapanisertib works in treating patients with acute lymphoblastic leukemia that has returned after a ...
About this study. This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
The purpose of this study is to determine the sensitivity of the Elephas Platform for predicting in-vivo clinical response based on surgical response or RECIST ...
Incidence of anterior cruciate ligament (ACL) ruptures disproportionately affect female athletes at a rate 4-6 times greater than male counterparts. In addition ...
- To assess the relationship between clinical effects (adverse event [AE] and/or tumor response) and CD38 receptor density at baseline (Part A). Participation ...
The purpose of this study is to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes. Participation eligibility.
Expert faculty members guide research and education in Mayo Clinic's Department of Quantitative Health Sciences.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.